Cannabidiol inhibits the skeletal muscle Nav1.4 by blocking its pore and by altering membrane elasticity.
Journal
The Journal of general physiology
ISSN: 1540-7748
Titre abrégé: J Gen Physiol
Pays: United States
ID NLM: 2985110R
Informations de publication
Date de publication:
03 05 2021
03 05 2021
Historique:
received:
08
07
2020
revised:
13
12
2020
revised:
19
01
2021
accepted:
16
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
16
10
2021
Statut:
ppublish
Résumé
Cannabidiol (CBD) is the primary nonpsychotropic phytocannabinoid found in Cannabis sativa, which has been proposed to be therapeutic against many conditions, including muscle spasms. Among its putative targets are voltage-gated sodium channels (Navs), which have been implicated in many conditions. We investigated the effects of CBD on Nav1.4, the skeletal muscle Nav subtype. We explored direct effects, involving physical block of the Nav pore, as well as indirect effects, involving modulation of membrane elasticity that contributes to Nav inhibition. MD simulations revealed CBD's localization inside the membrane and effects on bilayer properties. Nuclear magnetic resonance (NMR) confirmed these results, showing CBD localizing below membrane headgroups. To determine the functional implications of these findings, we used a gramicidin-based fluorescence assay to show that CBD alters membrane elasticity or thickness, which could alter Nav function through bilayer-mediated regulation. Site-directed mutagenesis in the vicinity of the Nav1.4 pore revealed that removing the local anesthetic binding site with F1586A reduces the block of INa by CBD. Altering the fenestrations in the bilayer-spanning domain with Nav1.4-WWWW blocked CBD access from the membrane into the Nav1.4 pore (as judged by MD). The stabilization of inactivation, however, persisted in WWWW, which we ascribe to CBD-induced changes in membrane elasticity. To investigate the potential therapeutic value of CBD against Nav1.4 channelopathies, we used a pathogenic Nav1.4 variant, P1158S, which causes myotonia and periodic paralysis. CBD reduces excitability in both wild-type and the P1158S variant. Our in vitro and in silico results suggest that CBD may have therapeutic value against Nav1.4 hyperexcitability.
Identifiants
pubmed: 33836525
pii: 211970
doi: 10.1085/jgp.202012701
pmc: PMC8042605
pii:
doi:
Substances chimiques
NAV1.4 Voltage-Gated Sodium Channel
0
SCN4A protein, human
0
Voltage-Gated Sodium Channels
0
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM021342
Pays : United States
Informations de copyright
© 2021 Ghovanloo et al.
Références
Lancet Neurol. 2010 Apr;9(4):413-24
pubmed: 20298965
Br J Pharmacol. 2019 May;176(10):1568-1584
pubmed: 30074247
J Gen Physiol. 2011 Aug;138(2):249-70
pubmed: 21788612
J Gen Physiol. 1977 Apr;69(4):497-515
pubmed: 300786
Pharmacol Res Perspect. 2020 Dec;8(6):e00682
pubmed: 33169541
Annu Rev Pharmacol Toxicol. 1984;24:387-423
pubmed: 6203481
J Gen Physiol. 2012 Jun;139(6):507-16
pubmed: 22641643
Neurol Sci. 2005 Oct;26(4):194-202
pubmed: 16193245
Sci Rep. 2018 Apr 19;8(1):6304
pubmed: 29674667
Science. 2015 Dec 18;350(6267):aac5464
pubmed: 26680203
J Biol Chem. 2018 Oct 26;293(43):16546-16558
pubmed: 30219789
J Gen Physiol. 1983 May;81(5):613-42
pubmed: 6306139
Pharmacotherapy. 2013 Feb;33(2):195-209
pubmed: 23386598
Ann Neurol. 2011 Feb;69(2):328-40
pubmed: 21387378
J Neurophysiol. 1993 Dec;70(6):2313-25
pubmed: 8120584
Neurology. 1981 Nov;31(11):1423-8
pubmed: 7031501
Br J Pharmacol. 2011 Aug;163(7):1479-94
pubmed: 21175579
Cell. 1991 Mar 8;64(5):871-4
pubmed: 1848157
Muscle Nerve. 2013 May;47(5):632-48
pubmed: 23536309
Neuromuscul Disord. 1991;1(1):19-29
pubmed: 1822774
Br J Pharmacol. 2008 Jan;153(2):199-215
pubmed: 17828291
Psychopharmacology (Berl). 2012 Feb;219(3):859-73
pubmed: 21796370
Biophys J. 1998 Jun;74(6):2945-52
pubmed: 9635748
Cell Rep. 2018 Sep 18;24(12):3133-3145
pubmed: 30231997
Biophys J. 1984 Jul;46(1):15-27
pubmed: 6331543
Elife. 2020 Oct 22;9:
pubmed: 33089780
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):E93-102
pubmed: 22160714
J Chem Theory Comput. 2016 Jan 12;12(1):405-13
pubmed: 26631602
J Physiol. 2002 Mar 1;539(Pt 2):469-83
pubmed: 11882679
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
Neurology. 2004 Nov 23;63(10):1977
pubmed: 15557532
Br J Pharmacol. 2015 Oct;172(20):4790-805
pubmed: 26218440
Sci Rep. 2016 May 13;6:25974
pubmed: 27174182
J R Soc Interface. 2010 Mar 6;7(44):373-95
pubmed: 19940001
Neurology. 2004 Nov 9;63(9):1647-55
pubmed: 15534250
Prog Chem Org Nat Prod. 2017;103:103-131
pubmed: 28120232
J Vis Exp. 2010 Oct 13;(44):
pubmed: 20972414
Nature. 2018 May;557(7706):590-594
pubmed: 29769724
Br J Pharmacol. 2018 Jun;175(11):2097-2115
pubmed: 29574880
Neurology. 2007 Mar 27;68(13):1080-1
pubmed: 17389319
Channels (Austin). 2018;12(1):367-377
pubmed: 30362397
Neuron. 2005 Feb 3;45(3):379-88
pubmed: 15694325
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13111-13116
pubmed: 30518562
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11229-11234
pubmed: 28973916
J Comput Chem. 2008 Aug;29(11):1859-65
pubmed: 18351591
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
Curr Opin Neurol. 1995 Oct;8(5):402-10
pubmed: 8542048
Br J Pharmacol. 2010 May;160(1):130-41
pubmed: 20412070
Br J Pharmacol. 2007 Mar;150(5):613-23
pubmed: 17245363
Mol Pharmacol. 2005 Sep;68(3):680-9
pubmed: 15967874
Handb Exp Pharmacol. 2018;246:147-160
pubmed: 29460150
Curr Top Membr. 2016;78:479-509
pubmed: 27586293
Trends Biochem Sci. 2020 May;45(5):369-371
pubmed: 32311330
Annu Rev Neurosci. 2006;29:387-415
pubmed: 16776591
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
J Physiol. 2004 Jan 15;554(Pt 2):321-34
pubmed: 14608015
Br J Pharmacol. 2020 Jul;177(13):2932-2946
pubmed: 32077098
Annu Rev Biophys Biomol Struct. 2007;36:107-30
pubmed: 17263662
J Gen Physiol. 2019 Mar 4;151(3):342-356
pubmed: 30796095
J Gen Physiol. 1995 Dec;106(6):1193-209
pubmed: 8786356
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Adv Genet. 2008;63:3-23
pubmed: 19185183
J Physiol. 2012 Jun 1;590(11):2577-89
pubmed: 22473783
Biophys J. 1993 Jul;65(1):270-88
pubmed: 8396455
Ann N Y Acad Sci. 1993 Dec 20;707:81-6
pubmed: 9137544
Brain. 2012 Sep;135(Pt 9):2585-612
pubmed: 22961543
Science. 2018 Oct 19;362(6412):
pubmed: 30190309
J Gen Physiol. 2004 May;123(5):599-621
pubmed: 15111647
J Comput Chem. 2011 Aug;32(11):2359-68
pubmed: 21541964
Eur J Hum Genet. 2008 Aug;16(8):921-9
pubmed: 18337730
J Gen Physiol. 2015 Dec;146(6):463-75
pubmed: 26573624
J Clin Invest. 2011 Oct;121(10):4082-94
pubmed: 21881211
Br J Pharmacol Chemother. 1946 Mar;1:38-61
pubmed: 20999334
Brain. 2016 Aug;139(Pt 8):2164-81
pubmed: 27267376
Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a003947
pubmed: 21746798
Front Physiol. 2020 Dec 22;11:610436
pubmed: 33414724
Science. 1990 Nov 30;250(4985):1256-9
pubmed: 1700867
Compr Physiol. 2015 Apr;5(2):761-90
pubmed: 25880512
J Phys Chem B. 2010 Jun 17;114(23):7830-43
pubmed: 20496934
Mol Pharmacol. 1994 Oct;46(4):716-25
pubmed: 7969051
Ann Neurol. 2000 Jan;47(1):46-53
pubmed: 10632100
Biophys J. 1989 Nov;56(5):1037-41
pubmed: 2605294
Elife. 2019 Sep 30;8:
pubmed: 31566564
Biophys J. 1996 Dec;71(6):3098-109
pubmed: 8968581
Acta Myol. 2008 Dec;27:98-113
pubmed: 19472919
Front Pharmacol. 2013 Jun 21;4:78
pubmed: 23801963
J Biol Chem. 2008 Jun 6;283(23):16124-34
pubmed: 18390906
Nature. 2000 Mar 2;404(6773):84-7
pubmed: 10716447
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
Brain. 2001 Jun;124(Pt 6):1091-9
pubmed: 11353725
J Comput Chem. 2014 Oct 15;35(27):1997-2004
pubmed: 25130509
Br J Pharmacol. 2019 May;176(10):1455-1469
pubmed: 29981240
Neurology. 2008 Mar 4;70(10):755-61
pubmed: 17898326
Neuropharmacology. 2020 May 1;167:107740
pubmed: 31437433
Br J Pharmacol. 2001 Oct;134(4):845-52
pubmed: 11606325